 Library
of Slides and Posters |
|
Hepatitis
B
|
|
|
Continued
Effi cacy and Safety Through 4 Years of Tenofovir
Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients
with Chronic Hepatitis B (Study 102)
P
Marcellin and others. AASLD 2010.
|
 |
TenofovirDisoproxilFumarate
(TDF) Versus EmtricitabinePlus TDF (FTC/TDF) for Treatment
of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication
Receiving AdefovirDipivoxil: Final Week 168 Results
T
Berg and others. AASLD 2010.
|
|
HBV
rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir
DF (TDF) Monotherapy or Combination Therapy with Emtricitabine
(FTC): an Evaluation of Early Viral Load Decay Kinetics
M
Curtis and others. AASLD 2010.
|
|
Four
Years Efficacy and Safety of Tenofovir Disoproxil
Fumarate (TDF) in Asians with HBeAg-Positive and HBeAg-Negative
Chronic Hepatitis B
E
Gane and others. AASLD 2010.
|
|
4
Year Efficacy of TenofovirDisoproxilFumarate
(TDF) in Chronic Hepatitis B Patients with High Viral Load
(HBV DNA .9 log10copies/mL)
S
Gordon and others. AASLD 2010.
|
|
Long
Term (4 Year) Effi cacy and Safety of Tenofovir
Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients
(HBeAg+) with Chronic Hepatitis B (Study 103)
E
Healthcote and others. AASLD 2010.
|
|
No
Resistance to Tenofovir Disoproxil Fumarate
(TDF) Detected Following up to 192 Weeks of Treatment in
Subjects Mono-Infected with Chronic Hepatitis B Virus
A
Snow-Lampart and others. AASLD 2010.
|
|
Long-term
Entecavir Treatment for Up to
5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results
From ETV-022 and -901
C Pan and others. AASLD 2010. |
|
Efficacy
and Safety of Entecavir in Nucleos(t)ide
Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis
B: Results from Studies ETV-022/027
R Gish and others. AASLD 2010.
|
|
Evaluation
of Amino Acid Substitutions in the Overlapping Envelope and Polymerase
Genes of HBV Among Treatment Naïve and Experienced Subjects Reveal
Significant Changes Associated with Lamivudine
and Adefovir, but not Tenofovir
DF Treatment
A
Snow-Lampart and others. AASLD 2010.
|
|
Hepatitis
C
|
|
Efficacy
and Safety of TMC435 in Combination With
Peginterferon a-2a and Ribavirin in Treatment-naïve
Genotype-1 HCV Patients: 24-Week Interim Results from the PILLAR Study
M
Fried and others. AASLD 2010.
|
|
In
vitro studies investigating the mechanism of interaction between
TMC435 and hepatic transporters
M
Huisman and others. AASLD 2010.
|
|
Virologic
analysis of genotype-1-infected patients treated with once-daily TMC435
during the Optimal Protease inhibitor Enhancement of Response to TherApy
(OPERA)-1 study
O
Lenz and others. AASLD 2010.
|
|
A
Phase IIa, open-label study to assess the antiviral activity of TMC435
monotherapy in patients infected with HCV genotypes 2–6
C
Moreno and others. AASLD 2010.
|
|
Pharmacokinetic-pharmacodynamic
analyses of TMC435 in patients
infected with hepatitis C virus genotypes 2–6
V
Sekar and others. AASLD 2010.
|
|
4-Week
Virologic Response and Safety of ABT-450
Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day Monotherapy
Then in Combination with Pegylated Interferon Alpha-2a and Ribavirin
(SOC) in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects
E
Lawitz and others. AASLD 2010. |
|
Initial
Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450
When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary
Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve
Subjects
E
Lawitz and others. AASLD 2010.
|
|
HCV
RESPOND-2 Final Results High Sustained Virologic Response Among Genotype
1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin
when Re- Treated with Boceprevir Plus PEGINTRON
(Peginterferon alfa-2b)/Ribavirin
B
Bacon and others. AASLD 2010.
|
|
Boceprevir
Combined with Peginterferon alfa-2b/Ribavirin for Treatment-Naïve
Patients with HCV Genotype 1
F
Poordad and others. AASLD 2010. |
|
Frequencies
of Resistance-Associated Amino Acid Variants Following Combination
Treatment with Boceprevir Plus PEGINTRON
(PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic
Hepatitis C (CHC), Genotype 1 (G1)
J
Vierling and others. AASLD 2010.
|
|
Hemoglobin
Decline During Lead-in Phase as an Early Predictor of Anemia After
the Addition of Boceprevir: A
Retrospective Analysis of HCV SPRINT-1
F
Poordad and others. AASLD 2010. |
|
Response-Guided
Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin
for Treatment-Naïve Patients with Hepatitis C Virus Genotype
1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir +
Peginterferon alfa-2b/Ribavirin in SPRINT-2
J
Bronowicki and others. AASLD 2010.
|
|
Strong
antiviral activity and safety of IFN-sparing treatment with the protease
inhibitor BI 201335, the HCV polymerase
inhibitor BI 207127, and ribavirin, in patients
with chronic hepatitis C: the SOUND-C1 trial
S Zeuzem and others. AASLD 2010. |
|
Virological
response and safety of 4 weeks’ treatment with the protease
inhibitor BI 201335 combined with 48 weeks of
peginterferon alfa 2a and ribavirin
for treatment of HCV GT-1 patients who failed peginterferon/ribavirin
T Berg and others. AASLD 2010.
|
|
Genotypic
and phenotypic analysis of the NS5B polymerase region from viral isolates
of HCV chronically infected patients treated with BI
207127 for 5 days’ monotherapy
L Lagace, and others. AASLD 2010.
|
|
BMS-790052,
a First-in-Class Potent Hepatitis C Virus NS5A Inhibitor, Demonstrates
Multiple-Dose Proof-of-Concept in Subjects With Chronic GT1 HCV Infection
R Nettles and others. AASLD 2010.
|
|
Coadministration
of BMS-790052 and BMS-650032 Does
Not Result in a Clinically Meaningful Pharmacokinetic Interaction
in Healthy Subjects
M Bifano and others. AASLD 2010.
|
|
Pipeline
Asset Update for BMS-790052 (NS5A inhibitor)
and BMS-650032 (NS3
inhibitor)
Btistol-Myers Squibb Company. AASLD 2010.
|
|
Combination
Therapy With BMS-790052 and BMS-650032 Alone
or With Pegylated Interferon and Ribavirin (pegIFN/RBV)
Results in Undetectable HCV RNA Through 12 Weeks of Therapy in HCV
Genotype 1 Null Responders
A Lok and others. AASLD 2010. |
|
BMS-824393
Is a Potent Hepatitis C Virus NS5A Inhibitor With Substantial Antiviral
Activity When Given as Monotherapy in Subjects With Chronic G1 HCV
Infection
R Nettles and others. AASLD 2010. |
|
Safety
and Antiviral Activity of MK-5172,
a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against
Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients
A
Petry and others. AASLD 2010.
|
|
Safety,
Tolerability, and Pharmacokinetics after Single and Multiple Doses
of MK-5172, a Novel HCV NS3/4a
Protease Inhibitor with Potent Activity Against Known Resistance Mutants,
in Healthy Subjects
A
Petry and others. AASLD 2010.
|
|
High
Correlation Between Week 4 and Week 12 as the Definition for Null
Response to Peginterferon alfa (PEG) Plus
Ribavirin (R) Therapy: Results From the IDEAL Trial
F
Poordad and others. AASLD 2010.
|
|
Impact
of PegIntron (PEG) Maintenance
Therapy (MT) on Fibrosis Biomarkers (FibroTest [FT]/FibroSURE) in
Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final
Results From the EPIC3 Program
T
Poynard and others. AASLD 2010.
|
|
The
Effect of Treatment Group, HCV Genotype, and IL28B Genotype on Early
HCV Viral Kinetics in a Phase 2a Study of PEG-Interferon
Lambda (pegIFNë) in Hepatitis C Patients
J Freeman and others. AASLD 2010.
|
|
Pegylated
Interferon Lambda (pegIFNë) Phase 2 Dose-Ranging,
Active-Controlled Study in Combination With Ribavirin
(RBV) for Treatment-Naive HCV Patients (Genotypes 1, 2,
3, or 4): Safety, Viral Response, and Impact of IL28B Host Genotype
Through Week 12
A Muir and others. AASLD 2010.
|
|
Pharmacokinetics
of PEG-Interferon Lambda (pegIFNë)
Following Fixed Dosing in Treatment-Naive Hepatitis C Subjects (Single-Dose
Interim Data From a Dose-Ranging Phase 2a Study)
K Byrnes-Blake and others. AASLD 2010.
|
|
Sustained
Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients
with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir
(MK-7009), a NS3/4a Protease Inhibitor, in Combination
with Pegylated Interferon Alfa-2a and Ribavirin
for 28 Days
M
Manns and others. AASLD 2010.
|
|
Genotypic
and Phenotypic Analysis of HCV NS5A Inhibitor
Resistance Variants: Correlations Between In Vitro and
In Vivo Observations
M Gao and others. AASLD 2010. |
|
|
Impaired
Fasting Glucose Is Associated With Lower Rates of Sustained Virologic
Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC):
Retrospective Analysis of the IDEAL Study
M
Sulkowski and others. AASLD 2010.
|
|
Analysis
of Site Performance in Academic and Community-Based Centers in the
IDEAL Study
J
Jou and others. AASLD 2010.
|
|
Baseline,
Donor, and On-treatment Predictors of Sustained Virologic Response
in Patients Treated for Recurrent Hepatitis C Following Orthotopic
Liver Transplant: Subanalysis of the PROTECT
Study
F
Gordon and others. AASLD 2010.
|
|
Chronic
Hepatitis C (HCV) Infections and the Risk
of Depression and Other Adverse Events
J McCombs and others. AASLD 2010. |
|
Sensitive
Detection of Y448H NS5B Mutant Viruses
in Patients Infected with Genotype 1a and 1b HCV
A
Bae and others. AASLD 2010.
|
|
Safety,
Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the
HCV NS3 Protease Inhibitor GS-9256
R
Goldwater and others. AASLD 2010.
|
|
Enhanced
in Vitro Antiviral Activity and Suppression of Resistance by Combining
GS-9256, A Novel Protease Inhibitor,
With GS-9190, a Non-Nucleoside
NS5B Inhibitor
H
Mo and others. AASLD 2010.
|
|
Antiviral
Response and Resistance Analysis of Treatment-Naïve HCV Infected
Subjects Receiving Single and Multiple Doses of GS-9190
J
Harris and others. AASLD 2010.
|
|
Nonclinical
Profi le and Phase I Results in Healthy Volunteers of the Novel and
Potent HCV NS5A Inhibitor GS-5885
J
Link and others. AASLD 2010.
|
|
Characterization
of HCV Resistance from Single and Multiple Dose Clinical Trials of
GS-9256, a Novel NS3 Protease Inhibitor
K
Wong and others. AASLD 2010.
|
|
Three-Day,
Dose-Ranging Study Of The HCV NS3 Protease Inhibitor
GS-9451
E
Lawitz and others. AASLD 2010.
|
|
Dual,
Triple, and Quadruple Combination Treatment with a Protease
Inhibitor (GS-9256) and a Polymerase Inhibitor (GS-9190)
alone and in Combination with Ribavirin(RBV) or PegIFN/RBV for up
to 28 days in Treatment Naïve, Genotype 1 HCV Subjects
S
Zeuzem and others. AASLD 2010.
|
